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Abstract
Objective
Healthcare workers (HCWs) are one of the target groups for systematic testing and treat-
ment of latent tuberculosis infection (LTBI) in a setting of low TB incidence. We performed
this study to describe the testing of HCWs for LTBI and analyse the acceptance and comple-
tion of treatment of LTBI.
Methods
This retrospective cohort study was conducted in four university-affiliated hospitals between
January 1 and December 31, 2018. HCWs with positive interferon-gamma release assay
(IGRA) during LTBI screening were analysed. We assessed the acceptance and completion
of LTBI treatment.
Results
Overall, 893 HCWs were IGRA positive. Among them, 609 HCWs visited the clinic for evalu-
ation of LTBI. Of 609 HCWs who were evaluated, 302 (49.6%) were offered treatment for
LTBI. The proportion of acceptance for treatment was 64.5% (195 of 302 HCWs). The treat-
ment course was completed by 143 of 195 HCWs (73.3%). Three months of isoniazid and
rifampin (3HR) was used in 137 HCWs (70.3%) and 4 months of rifampin (4R) in 58
(29.7%). 72 HCWs (36.9%) experienced at least one adverse drug events, but there was no
different characteristics between completer and non-completer.
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Conclusion
The acceptance and completion of LTBI treatment were unsatisfactory. Subjective perspec-
tive regarding obstacles to treatment of LTBI needs to be explored to increase compliance
to LTBI treatment.
Introduction
The diagnosis and treatment of latent tuberculosis infection (LTBI) are important [1] for elim-
inating tuberculosis (TB). The prevention of active TB disease by treating LTBI is a critical
component of the World Health Organization (WHO) End TB strategy [2].
Healthcare workers (HCWs) could be one of the target groups for the screening and treat-
ment of LTBI because of the relatively high risk of developing active TB compared with the
general population [3]. Based on the WHO 2018 guideline [4], HCWs are one of the target
groups for systematic testing and treatment of LTBI in a setting of low TB incidence.
There are several obstacles to scaling up of LTBI treatment in HCWs. Traditionally, the
acceptance of LTBI treatment among HCWs has been considered to be lower than that among
non-HCWs [5, 6] with poor completion rates for a long duration of LTBI treatment [5–8].
Besides, it is important to exclude active TB before initiating treatment for LTBI. Symptomatic
and radiographic screening has been used in the investigation of household contacts to exclude
active TB [4]. A previous study revealed minor TB lesions on chest computed tomography
(CT) in subjects with normal chest radiographs during contact investigation [9]. In the health
care setting, exclusion of active TB is important because of possible transmission to patients.
This study aimed to assess the process of LTBI evaluation in HCWs and analyse the treat-
ment acceptance and completion of 3–4 months of LTBI treatment. We also aimed to investi-
gate treatment outcomes among HCWs in South Korea.
Methods
Study design and population
This retrospective cohort study was conducted in four university-affiliated hospitals in Korea.
All HCWs from the four study hospitals who were positive for the interferon-gamma (IFN-γ)
release assay (IGRA) during LTBI screening in 2017 as part of the national TB elimination pro-
gram were enrolled [10, 11]. All participants who agreed to the testing of LTBI were screened
between January 1 and December 31, 2017. HCWs who had positive IGRA results were
enrolled in this study and followed up for the development of active TB until December 2018.
The electronic medical records of these HCWs were retrospectively reviewed. We reviewed
variables such as age, sex, body mass index (BMI), smoking, co-morbidities, and healthcare
professions. The research protocol was approved by the institute review board of each hospital
(approval numbers Institutional Review Board of Severance Hospital 4-2018-0960, Kangwon
National University Hospital Institutional Review Board 2018-06-008-001, Pusan National
University Yangsan Hospital Institutional Review Board 05-2019-044, Institutional Review
Board of Seoul National University Hospital 1806-011-948). The requirement for informed
consent was waived due to the retrospective nature of the study, in which all analyses used
anonymous clinical data and presented minimal risk. Each institute review board approved
the waiver of informed of consents.
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Evaluation for latent tuberculosis infection and tuberculosis
IGRA was performed using QuantiFERON-TB Gold In-Tube assay (Qiagen, Hiden, Germany)
in accordance with the manufacturer’s instruction. A positive IGRA result was defined as an
IFN-γ response to the TB antigen minus that of the Nil tube of� 0.35 IU/ml. Symptom screen-
ing and chest radiographs were evaluated to exclude active TB at the same time. If a lesion sus-
picious of tuberculosis was seen on the chest radiograph, sputum examination and chest
computed tomography (CT) were performed based on the discretion of the attending physi-
cian. Diagnosis of active TB was made based on all clinical, radiologic, and microbiological
information. Active pulmonary TB was confirmed by the culture of M. tuberculosis from
respiratory specimens, or by the presence of caseating granulomas in lung tissue or M. tuber-
culosis DNA. A culture-negative TB was defined for patients with high clinical likelihood of
active TB, and a negative mycobacterial culture finding for two or more sputum examinations,
but with good clinical and radiographic responses to anti-TB treatment during follow-up.
Treatment of latent tuberculosis infection
HCWs who had positive IGRA results were advised to visit a pulmonary or infectious depart-
ment out-patient clinic according to hospital policy. After medical evaluation and exclusion of
active tuberculosis, the LTBI treatment recommendation and regimens were determined
according to physician discretion. There was no case where HCW received treatment at a dif-
ferent hospital in this study. Treatment completion was defined as consumption of 80% of all
prescribed medications without loss to follow-up [12, 13]. The treatment was not carried by
directly observed treatment (DOT); instead, special TB nurses counseled and confirmed the
patients with medication. During each medical appointment, attending physicians checked
the patients’ compliance to medications by asking how many pills patients had taken. All side
effects (clinical and laboratory) were graded using the National Cancer Institute’s Common
Terminology Criteria for Adverse Effects (CTCAE). All participants were followed up until the
completion of LTBI treatment or loss to follow-up and data for the development of active TB
were reviewed from medical records until December 2018.
Statistical analysis
Continuous variables were reported as the median and range or interquartile range (IQR) and
categorical variables as percentages and frequencies. Continuous variables were analysed using
the Mann-Whitney U-test. Categorical variables were compared using the chi-square test or
the Fisher’s exact test. Differences were considered statistically significant at P < 0.05 (two-
tailed). All statistical analyses were performed using SPSS v18.0 (IBM, Armonk, NY, USA).
Results
Baseline characteristics of HCWs with positive IGRA results
Overall, 3,920 HCWs underwent IGRA between January and December, 2017. Among them,
893 HCWs (22.8%) were positive for IGRA in the four study hospitals, including 654 in hospi-
tal A, 104 in hospital B, 112 in hospital C, and 23in hospital D. The median age of all IGRA-
positive HCWs was 46 years (range 21–68), with 367 (41.1%) male subjects (Table 1). Of the
893 HCWs, 609 (68.2%) visited the clinic for evaluation of LTBI and active TB (Fig 1).
Exclusion of active TB in HCWs with positive IGRA
For the exclusion of active TB, chest radiographs were performed in all HCWs who were
IGRA positive. Chest CT was carried out in 21 HCWs (2.4%) for the evaluation of abnormal
Latent tuberculosis infection among healthcare workers
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lesions on the chest radiograph. No HCW had symptoms suggestive of TB, including cough
for more than 2 weeks, fever, weight loss, and night sweats. During the medical evaluation,
two HCWs were diagnosed with active pulmonary TB; one HCW was culture positive while
the other was culture negative. These HCWs were treated with standard anti-TB medication.
We calculated the sensitivity and specificity of chest X-ray for diagnosis of active TB. The
Table 1. Baseline characteristics IGRA positive HCWs.
Total
(N = 893)
Age (year), median, range 46 (21–68)
20–29, No (%) 78 (8.7)
30–39, No (%) 172 (19.3)
40–49, No (%) 372 (41.7)
50–59, No (%) 245 (27.5)
�60, No (%) 25 (2.8)
Gender; Male, No (%) 367 (41.1)
Site
Site A 654 (73.2)
Site B 104 (11.6)
Site C 112 (12.5)
Site D 23 (2.6)
BMI (kg/m2), median (IQR) 23.0 (21.0–25.0)
Smoking statusa
Never smoker 606 (74.1)
Ex-smoker 111 (13.6)
Current smoker 101 (12.3)
Profession
Administrative 197 (22.1)
Technicianb 92 (10.3)
Health aidc 266 (29.8)
Physician 99 (11.1)
Nurse 239 (26.8)
Work duration, month, median (IQR) 260 (117.7–315.8)
Comorbidities
HTN 96 (10.8)
DM 34 (3.8)
History of TB treatment 58 (6.5)
Chest radiography
No active lung lesion 873 (97.8)
Lesion suspicious of TB or others 20 (2.2)
Chest computed tomography performed 21 (2.4)
Active TB diagnosis 2 (0.2)
IFN- γ (TB Ag-Nil) concentration (IU/mL; median, IQR) 2.51 (0.92–6.13)
Data are presented as No (%) or median, range, and IQR.
aData of Smoking were available for 818 HCWs.
bTechnicians were defined as employees performing radiology, laboratory, or pathology-related duties.
cHealth aides were defined as employees performing physiotherapy and patient transfer services.
HCWs, health care workers; BMI, body mass index; IQR, interquartile range; TB, tuberculosis; HTN, hypertension;
DM, diabetes mellitus; IGRA, interferon-gamma release assay; IFN- γ, interferon gamma
https://doi.org/10.1371/journal.pone.0222810.t001
Latent tuberculosis infection among healthcare workers
PLOS ONE | https://doi.org/10.1371/journal.pone.0222810 September 19, 2019 4 / 11
sensitivity of the chest radiograph in for diagnosis of active TB was 50% (95% confidence inter-
val, CI, 2.7% to 97.3) and the specificity was 97.9% (95% CI, 96.6% to 98.7%).
Factors affecting the LTBI treatment recommendation by a physician
After exclusion of active TB, 302 HCWs (49.6%) were advised by physician to treat LTBI. Phy-
sician offered LTBI treatment less in those who were older, male, and with administrative pro-
fession. In multivariate regression analysis, physician offered LTBI treatment more in younger
HCWs with profession of health aids and nurses (Table 2).
Among 302 HCWs who were offered the treatment of LTBI, 195 HCWs (64.6%) accepted
the physician’s recommendation. When we compared the characteristics of HCWs between
acceptors and decliner of LTBI treatment, acceptors were younger than decliners.
Comparison of the characteristics between HCWs who completed
treatment and those who did not
Among 195 HCWs who commenced LTBI treatment, 143 (73.3%) completed the course of
treatment. We did not find any specific risk factors for non-completion of LTBI treatment
(Table 3). There was no difference in age, gender, profession, and duration of employment
Fig 1. Flow chart of the study. HCWs, health care workers; IGRA, interferon-gamma release assay; LTBI, latent tuberculosis infection.
https://doi.org/10.1371/journal.pone.0222810.g001
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between those who completed treatment and those who did not. 137 HCWs (70.3%) were
treated with 3 months of isoniazid and rifampin (3HR) and 58 (29.7%) with 4 months of rifam-
pin (4R). There was no difference between the two regimens in completion of treatment. More
than one-third of HCWs (36.9%) developed adverse drug events during treatment. There was
no difference in the incidence of adverse events between those who completed (35%) and
those who did not complete treatment (42.3%). However, HCWs who experienced the flu-like
symptoms more likely stopped the medication for LTBI (Table 3). Among 52 HCWs who did
not complete treatment, 22 (42.3%) stopped treatment due to adverse drug events.
Among those who failed to complete the treatment course, the majority of HCWs dropped
out in the early phase of treatment (Fig 2). More than a half of those who failed to complete the
treatment course (51.9%) dropped out within 2 weeks and 80% of those who dropped out did
not present for follow-up in the clinic at 5 weeks after commencement of treatment.
Comparison of the characteristics of HCWs according to the occurrence of
ADRs
For the treatment of LTBI, 72 HCWs (36.9%) experienced at least one ADR. The characteris-
tics were not different between HCWs with ADR and those without (Table 4). There was no
difference between the two regimens (3HR vs 4R) in the development of ADRs.
Discussion
We analysed the LTBI evaluation process and treatment outcomes regarding acceptance and
completion of treatment among HCWs.
Table 2. Factors affecting the LTBI treatment recommendation by a physician.
Visiting the clinic
(N = 609)
Treatment
offered (N = 302)
Bivariate
analysis
Multivariate analysis
Age (year), median, range 42 (21–62) 0.94 (0.92–0.95) 0.975 (0.95–0.99)
Gender, female No (%) 210 (69.5) 1.69 (1.21–2.37) 1.00 (0.56–1.80)
BMI (kg/m2), median (IQR) 22 (20.8–24.7) 0.92 (0.84–0.97) 0.98 (0.92–1.05)
Never smokera 228 (84.1) 2.05 (1.36–3.09) 1.12 (0.61–2.05)
HTN 18 (6.0) 0.52 (0.28–0.95) 0.92 (0.47–1.80)
DM 12 (4.0) 1.37 (0.56–3.30)
Profession
Administrative 38 (12.6) reference reference
Technicianb 23 (7.6) 1.79 (0.93–3.47) 1.27 (0.61–2.64)
Health aidc 97 (32.1) 2.28 (1.42–3.64) 1.70 (1.00–2.87)
Physician 25 (8.3) 2.38 (1.19–4.53) 1.86 (0.90–3.85)
Nurse 119 (39.4) 5.23 (3.19–8.59) 3.43 (1.88–6.28)
Working duration, month, median (IQR) 237.4 (103.5–296.8) 0.99 (0.99–1.00)
IFN-γ (TB Ag-Nil) concentration (IU/mL; median, IQR) 2.385 (0.878–5.865) 0.99 (0.97–1.02)
Data are presented as No (%) or median, range, and IQR
aData of Smoking were available for 572 HCWs.
bTechnicians were defined as employees performing radiology, laboratory, or pathology-related duties.
cHealth aides were defined as employees performing physiotherapy and patient transfer services.
LTBI, latent tuberculosis infection; BMI, body mass index; IQR, interquartile range; HTN, hypertension; DM, diabetes mellitus; IFN-γ, interferon gamma
https://doi.org/10.1371/journal.pone.0222810.t002
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HCWs are at high risk for developing active TB and LTBI compared to the general popula-
tion [3]. TB among HCWs is important because they are at risk of developing infection from
the work place. Besides, HCWs may transmit infection to patients in health care settings.
Therefore, regular screening for TB and LTBI among HCWs has been previously conducted in
low incidence settings [14, 15], although there were several controversial issues including cost-
effectiveness [16, 17]. Furthermore, the diagnosis and treatment of LTBI among HCWs in set-
tings of intermediate burden such as South Korea may help with the control of TB in health
care settings.
A significant number of HCWs did not visit the clinic for evaluation posing a major hin-
drance to systematic screening for LTBI and TB. In this study, only 68.2% of HCWs under-
went evaluation. Exclusion of active TB by symptom screening and chest radiography may
not be adequate in some cases. In the present study, all HCWs underwent chest radiogra-
phy. Active TB was diagnosed on chest CT and clinical situation in one HCW who was
Table 3. Comparison of the characteristics between HCWs who completed LTBI treatment vs. those who did not.
Characteristic Total
(N = 195)
Completed
(N = 143)
Did not complete
(N = 52)
P
Age (year), median, range 40 (21–62) 41 (21–59) 39 (23–62) 0.803
Gender,female, No (%) 138 (70.8) 101 (70.6) 37 (71.2) 0.943
BMI (kg/m2), median (IQR) 22 (21–24) 22 (21–24) 22 (20–24) 0.421
Never smokera 150 (88.8) 109 (87.2) 41 (93.2)
HTN 11 (5.6) 9 (6.3) 2 (3.8) 0.731
DM 7 (3.6) 5 (3.5) 2 (3.8) 1.000
Profession 0.544
Administrative 17 (8.7) 12 (8.4) 5 (9.6)
Technicianb 26 (8.2) 9 (6.3) 7 (13.5)
Health aidc 65 (33.3) 48 (33.6) 17 (32.7)
Physician 18 (9.2) 13 (9.1) 5 (9.6)
Nurse 79 (40.5) 61 (42.7) 18 (34.6)
Work duration, month, median (IQR) 184.2 (65.5–290.7) 181.9 (69.8–287.1) 186.2 (29.0–296.8) 0.952
Any adverse drug events 72 (36.9) 50 (35.0) 22 (42.3) 0.347
Abnormal liver functiond 18 (9.1) 13 (9.1) 5 (9.6) 1.000
Fatigue 28 (14.4) 19 (13.3) 9 (17.3) 0.479
Gastrointestinal symptoms 19 (9.7) 12 (8.4) 7 (13.5) 0.291
Rash 12 (6.2) 7 (4.9) 5 (9.6) 0.309
Pruritus 9 (4.6) 7 (4.9) 2 (3.8) 1.000
Flu-like symptoms 8 (4.1) 2 (1.4) 6 (11.5) 0.005
Regimen
3HR 137 (70.3) 100 (69.9) 37 (71.1) 0.869
4R 58 (29.7) 43 (30.1) 15 (28.8)
Data are presented as No (%) median, range, and IQR.
aData of Smoking were available for 169 HCWs.
bTechnicians were defined as technical employees performing radiology, laboratory, or pathology-related duties.
cHealth aids were defined as employees performing physiotherapy and patient transfer services.
dAbnormal liver function means an elevation of alanine/aspartate aminotransferase by more than three times the upper limit of normal range if baseline was normal
based on CTCAE version 5.0.
LTBI, latent tuberculosis infection; HCWs, health care workers; BMI, body mass index; IQR, interquartile range; HTN, hypertension; DM, diabetes mellitus; 3HR, 3
months of isoniazid and rifampin; 4R 4 months of rifampin.
https://doi.org/10.1371/journal.pone.0222810.t003
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asymptomatic and had no suspicious lesions on the chest radiograph. He had minor find-
ings suggestive of active TB on the chest CT and was culture negative for mycobacteria. He
was diagnosed and treated based on the clinical judgement of the attending physician.
Pooled sensitivity and specificity of symptom screening and abnormal chest radiograph to
rule out active TB in subjects with human immunodeficiency virus (HIV) infection on anti-
retroviral therapy (ART) was 89.3% (95% CI, 82.6–93.6) and 27.2% (95% CI, 17.3–40.0) [4]
in a previous report. Thus, in some cases, the sensitivity and specificity of chest radiography
and symptom screening are not enough for the exclusion of active TB in the intermediate
and high burden setting. Physicians need to exercise caution and exclude active TB before
the commencement of treatment for LTBI in these settings.
The low acceptance rate (64.6%) for LTBI treatment among HCWs was another impedi-
ment in the present study, consistent with previous reports [18]. One-third of the Korean pop-
ulation were infected with M. tuberculosis bacilli, and the infection rate increased with age
[19]. IGRA screening among employees aged more than 60 years working in congregated facil-
ities showed more than 40% positive for IGRA in South Korea [10]. Besides, the incidence of
adverse events increased with age. Thus, many HCWs in the older age group were reluctant to
undergo treatment for LTBI. In the present study, we found a variation in the acceptance for
the treatment of LTBI between study sites ranging from 52% to 98%. The wide range of
Fig 2. Drop out of LTBI treatment among 52 healthcare workers who did not complete treatment. Among the 52 HCWs who did not complete treatment, most
dropped out in the early phase of treatment. In the first 2 weeks, 51.9% HCWs dropped out; 80% of those who did not complete treatment did not present for follow up
after 5 weeks. SE, side effect.
https://doi.org/10.1371/journal.pone.0222810.g002
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acceptance in our study implies the possibility of different target populations among HCWs
and variable levels of recommendation by attending physicians at study sites.
The completion rate of LTBI in this study was 73.3% which is comparable to previous
reports [17, 20]. The absence of difference in characteristics between subjects who completed
treatment and those who did not was surprising. Among those who did not complete treat-
ment, 22 HCWs (42.3%) stopped treatment due to adverse events, while the rest (57.7%)
dropped out without specific reasons. The relatively early dropout among those who did not
complete treatment (Fig 2) may imply that HCWs accepted the LTBI treatment initially, but
were unsure about continuing the full course of treatment.
Shorter regimens for LTBI have been developed to improve treatment compliance com-
pared to the 9-month isoniazid regimen (9H). Recently, 12 doses of rifapentine and isoniazid
have been recommended [21]; besides, 4R has shown comparable efficacy to 9H [12]. In the
present study, HCWs were treated with 3HR or 4R according to physician discretion. There
was no difference in completion and the occurrence of adverse events between two regimens.
There are several limitations to the present study. Although this was a multicentre study,
only 4 centres were involved. All HCWs in this study were enrolled in the national TB elimina-
tion program, which was conducted in accordance with the Tuberculosis Prevention Act.
Therefore, we could not generalize these results in other settings for evaluation of LTBI in
HCWs. There were several missing data in basic characteristics, including smoking, co-mor-
bidity and history of TB exposure. In addition, we could not assess the real barriers for accep-
tance and completion of treatment from the perspective of the HCW’s. Hence, qualitative
Table 4. Comparison of the characteristics between HCWs who experienced ADRs or not.
Characteristic Total
(N = 195)
ADRs negative
(N = 123)
ADRs positive
(N = 72)
P
Age (year), median, range 40 (21–62) 38.9 (29.3–47) 42 (34.8–47.5) 0.100
Gender; female, No (%) 138 (70.8) 88 (71.5) 50 (69.4) 0.756
BMI (kg/m2), median (IQR) 22.0 (21.0–24.0) 22.4 (20.8–24.9) 22.0 (20.0–24.0) 0.138
Never smokera 150 (88.8) 95 (89.6) 55 (87.3) 0.644
HTN 11 (5.6) 4 (3.3) 7 (9.7) 0.103
DM 7 (3.6) 3 (2.4) 4 (5.6) 0.427
Profession 0.061
Administrative 17 (8.7) 7 (5.7) 10 (13.9)
Technicianb 26 (8.2) 13 (10.6) 3 (4.2)
Health aidc 65 (33.3) 36 (29.3) 29 (40.3)
Physician 18 (9.2) 13 (10.6) 5 (6.9)
Nurse 79 (40.5) 54 (43.9) 25 (34.7)
Work duration, month, median (IQR) 184.2 (65.5–290.65) 153.7 (40.7–282.7) 213.1 (93.6–294.7) 0.325
Regimen 0.607
3HR 137 (70.3) 88 (71.5) 49 (68.1)
4R 58 (29.7) 35 (28.5) 23 (31.9)
Completion of treatment 143 (73.3) 93 (75.6) 50 (69.4) 0.347
aData of Smoking were available for 169 HCWs.
bTechnicians were defined as technical employees performing radiology, laboratory, or pathology-related duties.
cHealth aids were defined as employees performing physiotherapy and patient transfer services.
ADRs, adverse drug reactions; HCWs, health care workers; BMI, body mass index; IQR, interquartile range; HTN, hypertension; DM, diabetes mellitus; 3HR, 3 months
of isoniazid and rifampin; 4R 4 months of rifampin.
https://doi.org/10.1371/journal.pone.0222810.t004
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research is required to further explore the obstacles to treatment from the perspective of
subjects.
Conclusions
In conclusion, the acceptance and completion of LTBI treatment were unsatisfactory. How-
ever, the factors affecting the completion of treatment was not clear. For scaling up of screen-
ing and treatment of LTBI, qualitative research to explore the subjective personal obstacles
may be helpful.
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